Physician profile
Patrick J Arambula
NPI 1396709762
$1,484.15
in general payments reported to CMS, 2019-2025
12 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $134 · 2021: $242 · 2022: $338 · 2023: $336 · 2024: $131 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $316.02 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $251.73 | 2019-2025 | Bexsero, Penmenvy, Rotarix |
| Pfizer INC. | $200.94 | 2020-2025 | |
| Sanofi Pasteur INC. | $166.61 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $164.61 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Sobi, INC | $114.81 | 2021-2023 | |
| Phadia US INC. | $110.24 | 2020-2024 | Immunocap |
| Boston Scientific Corporation | $47.38 | 2022-2025 | General - Pain Management |
| Ultragenyx Pharmaceutical INC. | $45.74 | 2023 | |
| Seqirus USA INC | $32.06 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Lnhc, INC | $18.01 | 2025 | Zelsuvmi |
| Alexion Pharmaceuticals, INC. | $16.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Arambula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.